38 research outputs found
ΠΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠΎΠ΄Π΅Π»Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΠΊΠΎΡΠΎΡΡΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΉ Π³Π΅Π½ΠΎΠΌΠ½ΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ²
Aim of study. To evaluate clinical significance of different combinations of gene polymorphisms IL-1b, IL-6, IL-10, TNF, HFE, TGF-b, ATR1, NOS3894, CYBA, AGT, MTHFR, FII, FV, FVII, FXIII, ITGA2, ITGB3, FBG, PAI and their prognostic value for prediction of liver fibrosis progression rate in patients with chronic hepatitis C (CHC).Subjects and methods: 118 patients with CHC were divided into Β«fastΒ» and Β«slowΒ» (fibrosis rate progression β₯0,13 and 0,13 fibrosis units/yr; n =64 and n =54) fibrosis groups. Gene polymorphisms were determined. Statistical analysis was performed using Statistica 10.Results. A allele (p =0,012) and genotype AA (p =0,024) of AGT G-6T gene, as well as T allele (p =0,013) and MT+TT genotypes (p =0,005) of AGT 235 M/T gene were significantly more common in Β«fast fibrosersΒ» than in Β«slow fibrosersΒ». Patients with genotype TT of CYBA 242 C/T had a higher fibrosis progression rate than patients with CC+CT genotype (p =0,02). Our analysis showed a protective effect of TT genotype of ITGA2 807 C/T on fibrosis progression rate (p =0,03). There was a trend (p 0,15) to higher fibrosis progression rate in patients with mutant alleles and genotypes of TGFb +915 G/C, FXIII 103 G/T, PAI -675 5G/4G genes. Other gene polymorphisms were not associated with enhanced liver fibrosis. To build a mathematical model for prediction of liver fibrosis progression rate we performed coding with scores for genotypes and virus genotype. Total score correlated with the fibrosis progression rate (R =0,39, p =0,000).Conclusion: Determination of genetic profile of the patient and virus genotype allows to predict the course of CHC.Β ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π±ΠΎΠ»ΡΡΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»ΡΠ΅ΡΡΡ ΠΏΠΎΠΈΡΠΊΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΎΠ±ΡΡΡΠ½ΡΡΡΠΈΡ
ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (Π₯ΠΠ‘).Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΡΠ΅Π½ΠΈΡΡ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²Π° ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΉ Π°Π»Π»Π΅Π»ΡΠ½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½ΠΎΠ² IL 1b, IL 6, IL 10, TNF Ξ±, HFE, TGF b, ATR1, NOS3, CYBA, AGT, MTHFR, FII, FV, FVII, FXIII, ITGA2, ITGB3, FBG, PAI Π½Π° ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΏΡΠΈ Π₯ΠΠ‘.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: 118 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠ‘ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° Π³ΡΡΠΏΠΏΡ Ρ Π±ΡΡΡΡΡΠΌ ΠΈ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΡΠΌ (ΡΠΊΠΎΡΠΎΡΡΡ ΡΠΈΠ±ΡΠΎΠ·Π° β₯0,13 ΠΈ 0,13 Π΅Π΄. ΡΠΈΠ±ΡΠΎΠ·Π°/Π³ΠΎΠ΄; n =64 ΠΈ n =54, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ) ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ. ΠΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ°. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΡΡ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΠ°ΠΊΠ΅ΡΠΎΠ² ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ Statistica 10.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π±ΡΡΡΡΡΠΌ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π³ΡΡΠΏΠΏΠΎΠΉ Ρ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΡΠΌ ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Π°Π»Π»Π΅Π»Ρ Π (Ρ =0,012) ΠΈ ΠΌΡΡΠ°Π½ΡΠ½ΡΠΉ Π³Π΅Π½ΠΎΡΠΈΠΏ ΠΠ (Ρ =0,024) Π³Π΅Π½Π° AGT G-6T, ΡΠ°ΠΊΠΆΠ΅ Π² Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΠ°ΡΠ΅ Π²ΡΡΠ²Π»ΡΠ»ΠΈ Π°Π»Π»Π΅Π»Ρ Π’ (Ρ =0,013) ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏ ΠΠ’+Π’Π’ Π³Π΅Π½Π° AGT 235 M/T (Ρ =0,005). ΠΠΎΠ»ΡΠ½ΡΠ΅ Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π’Π’ Π³Π΅Π½Π° CYBA 242 C/T ΠΈΠΌΠ΅Π»ΠΈ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΡΡ ΡΠΊΠΎΡΠΎΡΡΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π‘Π‘+Π‘Π’ (Ρ =0,02). Π Ρ
ΠΎΠ΄Π΅ Π°Π½Π°Π»ΠΈΠ·Π° Π²ΡΡΠ²Π»Π΅Π½ΠΎ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π³ΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡΡ Π’Π’ Π³Π΅Π½Π° ITGA2 807 C/T Π½Π° ΡΠ΅ΠΌΠΏΡ ΡΠΈΠ±ΡΠΎΠ·Π° (Ρ =0,03). ΠΠ°Π±Π»ΡΠ΄Π°Π»ΠΈΡΡ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ ΠΊ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΠΎ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π°Π»Π»Π΅Π»Π΅ΠΉ ΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² TGFb +915 G/Π‘, FXIII 103 G/T, PAI -675 5G/4G ΠΌΠ΅ΠΆΠ΄Ρ Π΄Π²ΡΠΌΡ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ. ΠΠ»Ρ ΠΎΡΡΠ°Π»ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ² Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ
ΠΎΡΠ»ΠΈΡΠΈΠΉ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ. Π Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌ ΠΏΠΎΡΡΡΠΎΠ΅Π½Π° ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠΎΠ΄Π΅Π»Ρ, ΡΡΠΈΡΡΠ²Π°ΡΡΠ°Ρ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈ ΠΏΡΠΎΡΠΈΠ±ΡΠΎΠ³Π΅Π½Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π³Π΅Π½ΠΎΠ², Π² ΡΠ°ΠΊΠΆΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π²ΠΈΡΡΡΠ°. ΠΡΡΠ²Π»Π΅Π½Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΌΠΌΠΎΠΉ Π±Π°Π»Π»ΠΎΠ² Π² ΡΡΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΈ ΡΠ΅ΠΌΠΏΠΎΠΌ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° Π² ΠΏΠ΅ΡΠ΅Π½ΠΈ (R =0,39, p =0,000).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Π°Ρ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠΎΠ΄Π΅Π»Ρ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»Π΅Π·Π½ΠΈ
Π‘Π½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΠΌΠΎΡΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Klotho Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ ΠΏΠΎΡΠ΅ΠΊ: ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅
Objective: to determine the role of serum Klotho (s-Klotho) protein levels changes in patients with different stages of chronic kidney disease (CKD).Methods: The study involved 130 patients with CKD stages 1β5D (mean age β 41Β±6.7 years). Serum levels of parathyroid hormone (PTH), calcium,Β phosphorus and s-Klotho protein (ELISA method) at baseline and after 1 year of follow-up were examined in all the patients so as the bloodΒ pressure (BP), including central (aortic), pulse wave velocity β with the help of Β«SphygmΠΎcorΒ» (Australia), echocardiography, radiography of theΒ abdominal aorta in a lateral projection were also performed.Results: when comparing the s-Klotho levels in patients with different CKD stages, itΒ was found that the level change associated with the reduction of glomerular filtration rate (GFR) ahead of phosphorus and PTH increase in serum,Β stared at 3A CKD, whereas hyperphosphatemia and PTH increase started at 4β5 CKD stages. According to ROC analysis, decreasing of s-KlothoΒ levels below 387 pg/ml was indicated a calcification risk of abdominal aorta increased with an 80% sensitivity and 75% specificity. In addition,Β a strong negative relationship of low s-Klotho levels and heart remodeling was found. When comparing the patients with hypertension who wereΒ receiving antihypertensive monotherapy, the highest serum levels of Klotho protein were observed in those of them whose target blood pressure levelΒ was achieved primarily through Angiotensin II Receptors Blockers (ARB), compared to those who was administered another drug group (p0.01)Β or has not reached the target blood pressure level (p=0,008).Conclusion: The change of serum Klotho levels (decrease) in CKD progression isΒ associated with the degree (increase) of cardiovascular calcification and remodeling (the development of left ventricular hypertrophy, and cardiomyopathy)Β and it can be seen as an early independent marker of the cardiovascular system lesions in CKD. Our preliminary data of the effect ofΒ blood pressure correction on s-Klotho levels may indicate the possibility of drug maintaining serum Klotho levels and it requires further research.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ Π±Π΅Π»ΠΊΠ° Klotho (s-Klotho) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ ΠΏΠΎΡΠ΅ΠΊ (Π₯ΠΠ) 1β5D ΡΡΠ°Π΄ΠΈΠΉ.ΠΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 130 Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠ 1β5D ΡΡΠ°Π΄ΠΈΠΉ (67 ΠΌΡΠΆΡΠΈΠ½ ΠΈ 63 ΠΆΠ΅Π½ΡΠΈΠ½Ρ; ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡΒ 41Β±6,7 Π³ΠΎΠ΄Π°). ΠΡΠΈΡΠΈΠ½Π°ΠΌΠΈ Π₯ΠΠ Ρ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Π±ΡΠ»ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π³Π»ΠΎΠΌΠ΅ΡΡΠ»ΠΎΠ½Π΅ΡΡΠΈΡ β Ρ 30, ΡΡΠ±ΡΠ»ΠΎΠΈΠ½ΡΠ΅ΡΡΡΠΈΡΠΈΠ°Π»ΡΠ½ΡΠΉ Π½Π΅ΡΡΠΈΡΒ (Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ, ΠΏΠΎΠ΄Π°Π³ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ) β Ρ 23, ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ· ΠΏΠΎΡΠ΅ΠΊ β Ρ 22, Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΡΠΉ Π½Π΅ΡΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ· β Ρ 28, ΡΠ°Ρ
Π°ΡΠ½ΡΠΉ Π΄ΠΈΠ°Π±Π΅ΡΒ 2-Π³ΠΎ ΡΠΈΠΏΠ° β Ρ 27. Π£ Π²ΡΠ΅Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ ΠΈ ΡΠ΅ΡΠ΅Π· 1 Π³ΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΡΠ΅ ΡΡΠΎΠ²Π½ΠΈ ΠΏΠ°ΡΠ°ΡΠΈΡΠ΅ΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ Π³ΠΎΡΠΌΠΎΠ½Π° (ΠΠ’Π),Β ΠΊΠ°Π»ΡΡΠΈΡ, ΡΠΎΡΡΠΎΡΠ°, Π±Π΅Π»ΠΊΠ° s-Klotho (ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ELISA). ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ (ΠΠ), Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ (Π°ΠΎΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ), ΡΠΊΠΎΡΠΎΡΡΡ ΠΏΡΠ»ΡΡΠΎΠ²ΠΎΠΉ Π²ΠΎΠ»Π½Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ° SphygmΠΎCor (ΠΠ²ΡΡΡΠ°Π»ΠΈΡ); Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΡΡ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡ, ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΡΠΈΡ Π±ΡΡΡΠ½ΠΎΠΉ Π°ΠΎΡΡΡ Π² Π±ΠΎΠΊΠΎΠ²ΠΎΠΉ ΠΏΡΠΎΠ΅ΠΊΡΠΈΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΡΡΠΎΠ²Π½Ρ s-Klotho Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠ°Π·Π½ΡΠΌΠΈ ΡΡΠ°Π΄ΠΈΡΠΌΠΈ Π₯ΠΠ ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ, ΡΡΠΎ ΠΏΠΎ ΠΌΠ΅ΡΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΊΠ»ΡΠ±ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ (Π‘ΠΠ€) Π΅Π³ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ Π½Π°ΡΠΈΠ½Π°Π΅ΡΡΡ ΡΠΆΠ΅ Ρ 3Π ΡΡΠ°Π΄ΠΈΠΈ Π₯ΠΠ ΠΈΒ ΠΎΠΏΠ΅ΡΠ΅ΠΆΠ°Π΅Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΎΡΡΠΎΡΠ° ΠΈ ΠΠ’Π, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Ρ 4β5-ΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π₯ΠΠ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ROC-Π°Π½Π°Π»ΠΈΠ·Ρ, Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ s-Klotho Π½ΠΈΠΆΠ΅Β 387 ΠΏΠ³/ΠΌΠ» Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ 80% ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡΡ 75% ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°Π»ΠΎ ΠΎΠ± ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠΈ ΡΠΈΡΠΊΠ° ΠΊΠ°Π»ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ aΠ±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉΒ Π°ΠΎΡΡΡ. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π²ΡΡΠ²Π»Π΅Π½Π° cΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠ°Ρ ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½Π°Ρ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ Π½ΠΈΠ·ΠΊΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ s-Klotho c ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅ΡΠ΄ΡΠ°Β (ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π³ΠΈΠΏΠ΅ΡΡΡΠΎΡΠΈΠΈ Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° ΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈ). ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΡΡ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ, Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π±Π΅Π»ΠΊΠ° s-Klotho ΠΎΡΠΌΠ΅ΡΠ΅Π½ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Ρ ΠΊΠΎΡΠΎΡΡΡ
ΡΠ΅Π»Π΅Π²ΠΎΠΉ ΡΡΠΎΠ²Π΅Π½ΡΒ ΠΠ Π±ΡΠ» Π΄ΠΎΡΡΠΈΠ³Π½ΡΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π±Π»ΠΎΠΊΠ°ΡΠΎΡΠΎΠ² ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΊ Π°Π½Π³ΠΈΠΎΡΠ΅Π½Π·ΠΈΠ½Ρ II, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠ΅ΠΌΠΈ, ΠΊΡΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»Β Π΄ΡΡΠ³ΠΈΠ΅ Π³ΡΡΠΏΠΏΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² (Ρ0,01) ΠΈΠ»ΠΈ Π½Π΅ Π΄ΠΎΡΡΠΈΠ³ ΡΠ΅Π»Π΅Π²ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΠΠ (p=0,008).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ KlothoΒ (ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅) ΠΏΠΎ ΠΌΠ΅ΡΠ΅ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π₯ΠΠ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΄ΡΠ° ΠΈ ΠΊΠ°Π»ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠ΅ΡΠ΄ΡΠ° ΠΈΒ ΡΠΎΡΡΠ΄ΠΎΠ² ΠΈ ΠΌΠΎΠΆΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΡΠ°Π½Π½Π΅Π³ΠΎ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΡΠΈ Π₯ΠΠ.Β ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π½Π°ΠΌΠΈ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠΈ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ ΠΠ Π½Π° ΡΡΠΎΠ²Π΅Π½Ρ s-Klotho ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ s-Klotho ΠΈ ΡΡΠ΅Π±ΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ
Π‘Π²ΡΠ·Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½ΠΎΠ² ΡΠ΅Π½ΠΈΠ½-Π°Π½Π³ΠΈΠΎΡΠ΅Π½Π·ΠΈΠ½ΠΎΠ²ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΈΒ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ ΡΒ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΒ ΡΡΠΆΠ΅ΡΡΡΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ ΡΒ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘
Background: At present, much attention is paid to genetic factors explaining the clinical course of chronic hepatitis C. Aim: To evaluate an association of the gene polymorphisms involved in the formation of endothelial dysfunction (NOS3 894G/T, CYBA 242C/T, MTHFR 677C/T) and encoding components of the renin-angiotensin system (ATR1 1166A/C, AGT (-6)G/T and 235M/T) with development and severity of portal hypertension syndrome in patients with chronic hepatitis C. Materials and methods: 162 patients with chronic hepatitis C and HCV-related cirrhosis (114 women and 48 men) were divided into the following groups: no portal hypertension (n = 98), "compensated" (n = 19) and "decompensated" (n = 45) portal hypertension. The gene polymorphisms were assessed by molecular genetic methods. Results: TT genotype of CYBA was more common in patients with portal hypertension than in those without (odds ratio (OR) for TT = 3.59, p = 0.031). This difference becomes larger when comparing the decompensated portal hypertension group with the no portal hypertension group (OR TT = 5.46, p = 0.009). Other gene polymorphisms were not associated with development or decompensation of portal hypertension. Multivariate analysis of the impact of genetic, clinical and demographic factors showed that portal hypertension was associated primarily with patients age at the time of the study (Wald's Ρ
2 = 14.99) and with their body mass index (Wald's Ρ
2 = 4.35). After exclusion of these population-wide risk factors from the model, the development of portal hypertension correlated with the carriage of 235TT genotype of CYBA (Wald's Ρ
2 = 6.07, OR = 4.29) and (-6)AA genotype AGT (Wald's Ρ
2 = 4.73, OR = 4.13), as well as with the lack of protective 235TT genotype AGT (Wald's Ρ
2 = 4.06, OR = 0.33). The combined effects of the studied gene polymorphisms on decompensation of the portal hypertension in patients with chronic HCV infection were similar. Conclusion: The development and increase in severity of portal hypertension syndrome in patients with chronic hepatitis C is directly correlated with the carriage of AA genotype of AGT (-6)G/A and TT genotype CYBA 242C/T and the absence of TT genotype AGT 235M/T.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. Π‘Π΅Π³ΠΎΠ΄Π½Ρ Π±ΠΎΠ»ΡΡΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»ΡΠ΅ΡΡΡ ΠΏΠΎΠΈΡΠΊΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΠΈΡ
Β ΡΠ΅ΡΠ΅Π½ΠΈΠ΅Β Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎΒ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘. Π¦Π΅Π»Ρ β ΠΎΡΠ΅Π½ΠΈΡΡΒ ΡΠ²ΡΠ·Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ°Β Π³Π΅Π½ΠΎΠ², Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½Π½ΡΡ
Β Π² ΡΠ°Π·Π²ΠΈΡΠΈΠ΅Β ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ (NOS3 894G/T, CYBA 242C/T, MTHFR 677C/T) ΠΈ ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΡ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡ ΡΠ΅Π½ΠΈΠ½-Π°Π½Π³ΠΈΠΎΡΠ΅Π½Π·ΠΈΠ½ΠΎΠ²ΠΎΠΉΒ Β ΡΠΈΡΡΠ΅ΠΌΡΒ Β (ATR1 1166A/C,Β AGT (-6)G/A ΠΈ 235M/T), Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈ Π½Π°ΡΠ°ΡΡΠ°Π½ΠΈΠ΅ΠΌ ΡΡΠΆΠ΅ΡΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈΒ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Β Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΒ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌΒ Π‘. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ.Β Π‘ΡΠΎ ΡΠ΅ΡΡΡΠ΄Π΅ΡΡΡ Π΄Π²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ ΠΈ ΡΠΈΡΡΠΎΠ·ΠΎΠΌ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π‘ (114 ΠΆΠ΅Π½ΡΠΈΠ½ ΠΈ 48 ΠΌΡΠΆΡΠΈΠ½) Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° Π³ΡΡΠΏΠΏΡ: Π±Π΅Π· ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ²Β ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈΒ (n = 98), Ρ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌΒ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ Π² ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ (n = 19) ΠΈ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ (n = 45) ΡΠ°Π·Π΅. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π³Π΅Π½ΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.Β Π£Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²Β Ρ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΠΌΠΈΒ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉΒ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈΒ Β Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΒ Β ΡΠ°ΡΠ΅,Β ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ Π±Π΅Π·Β ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉΒ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ,Β Π²ΡΡΡΠ΅ΡΠ°Π»ΠΎΡΡ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° TT Π³Π΅Π½Π° CYBA (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅Β ΡΠ°Π½ΡΠΎΠ²Β (ΠΠ¨) TT = 3,59,Β Ρ = 0,031). ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈΒ Π³ΡΡΠΏΠΏ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²Β Ρ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉΒ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉΒ ΠΈ Π±Π΅Π· ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉΒ Β Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈΒ Β ΡΠ°Π·Π»ΠΈΡΠΈΡΒ Β Π½Π°ΡΠ°ΡΡΠ°Π»ΠΈ (ΠΠ¨ TT = 5,46, Ρ = 0,009). ΠΠ»Ρ ΠΎΡΡΠ°Π»ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΠ²Β Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ
Β Β ΡΠ°Π·Π»ΠΈΡΠΈΠΉΒ Β Π½Π΅Β ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ. ΠΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ²Β Π²ΡΡΠ²ΠΈΠ»: ΠΏΠΎΡΡΠ°Π»ΡΠ½Π°ΡΒ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡΒ Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡ ΠΏΡΠ΅ΠΆΠ΄Π΅Β Π²ΡΠ΅Π³ΠΎ Ρ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌΒ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π°Β ΠΌΠΎΠΌΠ΅Π½ΡΒ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΒ (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° ΟΒ² = 14,99) ΠΈ Ρ ΠΈΡ
ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° ΟΒ² = 4,35). ΠΠΎΡΠ»Π΅ ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΡ ΠΈΠ· ΠΌΠΎΠ΄Π΅Π»ΠΈ ΡΡΠΈΡ
ΠΎΠ±ΡΠ΅ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΡ
Β ΡΠ°ΠΊΡΠΎΡΠΎΠ²Β ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΎ Ρ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌ 235Π’Π’ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π³Π΅Π½Π° CYBA (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° ΟΒ² = 6,07, ΠΠ¨ = 4,29) ΠΈ (-6)ΠΠ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π³Π΅Π½Π° AGT (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° ΟΒ² = 4,73, ΠΠ¨ = 4,13) ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ 235Π’Π’ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π³Π΅Π½Π° AGT (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° ΟΒ² = 4,06, ΠΠ¨ = 0,33). ΠΠ½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠΌ Π±ΡΠ»ΠΎ ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ²Β Π½Π° Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΡΒ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉΒ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ.Β ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅.Β Π Π°Π·Π²ΠΈΡΠΈΠ΅Β ΠΈ Π½Π°ΡΠ°ΡΡΠ°Π½ΠΈΠ΅Β ΡΡΠΆΠ΅ΡΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°Β ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉΒ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘ ΠΏΡΡΠΌΠΎ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌΒ (-6)ΠΠ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π³Π΅Π½Π° AGT ΠΈ 242TΠ’ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π³Π΅Π½Π° CYBA ΠΈ Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ 235Π’Π’ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π³Π΅Π½Π° AGT
ΠΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΊΠΎΡΠΎΡΡΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΒ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌΒ Π‘Β Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈΒ ΡΡΠ΅Π΄ΠΎΠ²ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ²
Rationale: Search for predictors of aggressive course of chronic hepatitis C virus (HCV) infection in individual patients, including genetic studies, is consideredΒ to be a major urgentΒ goal. High rates of fibrosis progressionΒ in chronic HCV infection is associated with several gene polymorphismsΒ coding for the components of renin-angiotensin system and involved in the formation of endothelial dysfunction and oxidative stress.Aim: To develop a predictiveΒ modelΒ toΒ assessΒ theΒ probabilityΒ of rapid fibrosis progressionΒ in patientsΒ with chronic HCV infection based on the combination of the known genetic markers, clinical and demographic parameters.Materials and methods:Β One hundredΒ andΒ nineΒ patientsΒ withΒ chronicΒ HCVΒ infection (79 womenΒ and 30 men) of known duration and liver fibrosis were categorizedΒ into the groups with βrapid fibrosisβ (n = 54, the rate of fibrosis progression β₯ 0.13 fibrosis units / year) and with βslow fibrosisβΒ (n = 55, theΒ rateΒ of progression 0.13Β fibrosis units / year). PolymorphismsΒ of the studied genes were assessed by molecular genetic assays. Multivariate analysis of the influence of combination of geneticΒ variants, as well as of the interaction of genetic, clinical and demographic factors on the rate of fibrosis progressionΒ in the patients with chronic HCV infection was performed by logisticΒ regressionΒ Β method.Β Results:Β TheΒ rapid rate of fibrosis progressionΒ was significantly associated with patient'sΒ age at the time of infection (Wald statisticsΒ 14.955;Β p = 0.00011), male gender (Wald statisticsΒ 6.787;Β p = 0.00918),Β (-6)ΠΠ genotypeΒ of theΒ AGTΒ geneΒ carriageΒ (Wald statistics 6.512;Β p = 0.01072), 242Π’Π’-genotypeΒ of theΒ CYBA geneΒ Β (WaldΒ statisticsΒ Β 4.347;Β Β p = 0.03708),Β Β and 235ΠΠ’ genotype of the AGT geneΒ (Wald statistics 4.306; p = 0.03799). The model to predict the probability of rapid fibrosis progressionΒ in individuals with chronic HCV infection included the above mentioned factors; its use was demonstrated with two clinical cases.Conclusion: The analysis of the AGTΒ geneΒ (M235T andΒ G-6A loci) andΒ theΒ Π‘YBA geneΒ (C242TΒ locus) polymorphismsΒ areΒ relevant toΒ identify patientsΒ atΒ risk of rapidΒ liver fibrosis progression. In this case, 242Π’Π’ genotype of the CYBA geneΒ andΒ (-6)AA andΒ 235MT genotypes of the AGT geneΒ are consideredΒ unfavorable. To refine the prognosis, it is necessary to take into accountΒ demographic parameters (genderΒ and age at the moment of infection contraction), because male gender and older age of getting the infection would increase the probability of rapidly progressive of hepatitis C.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠΎΠΈΡΠΊ Ρ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΎΠ³ΠΎΒ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠ² Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (Π₯ΠΠ‘), Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ. ΠΡΡΡΡΡΠΉ ΡΠ΅ΠΌΠΏ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡΒ ΡΠΈΠ±ΡΠΎΠ·Π°Β ΠΏΡΠΈ Π₯ΠΠ‘ Π°ΡΡΠΎΡΠΈΠΈΡΡΠ΅ΡΡΡΒ Ρ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠΌ ΡΡΠ΄Π° Π³Π΅Π½ΠΎΠ², ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΡ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡΒ Β Β Β ΡΠ΅Π½ΠΈΠ½-Π°Π½Π³ΠΈΠΎΡΠ΅Π½Π·ΠΈΠ½ΠΎΠ²ΠΎΠΉΒ Β Β Β ΡΠΈΡΡΠ΅ΠΌΡ ΠΈ Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½Π½ΡΡ
Β Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉΒ Β Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈΒ ΠΈΒ ΠΎΠΊΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎΒ Β ΡΡΡΠ΅ΡΡΠ°.Π¦Π΅Π»Ρ β ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ°Β ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΎΡΠ΅Π½ΠΊΠΈ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΠΈ Π±ΡΡΡΡΠΎΠ³ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡΒ ΡΠΈΠ±ΡΠΎΠ·Π°Β Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Β Π₯ΠΠ‘Β Π½Π°Β ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈΒ Β ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
Β Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Β Β ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ²Β ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Β Β ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ².ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Β ΠΈΒ ΠΌΠ΅ΡΠΎΠ΄Ρ.Β Π‘ΡΠΎ Π΄Π΅Π²ΡΡΡΒ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΒ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉΒ Β HCV-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉΒ Β (79Β ΠΆΠ΅Π½ΡΠΈΠ½ ΠΈ 30 ΠΌΡΠΆΡΠΈΠ½) Ρ ΠΈΠ·Π²Π΅ΡΡΠ½ΠΎΠΉΒ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡΒ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ Π±ΡΠ»ΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° Π³ΡΡΠΏΠΏΡ Ρ Β«Π±ΡΡΡΡΡΠΌ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌΒ» (n = 54, ΡΠΊΠΎΡΠΎΡΡΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π°Β β₯ 0,13 Π΅Π΄. ΡΠΈΠ±ΡΠΎΠ·Π° / Π³ΠΎΠ΄)Β Β ΠΈΒ Β ΡΒ Β Β«ΠΌΠ΅Π΄Π»Π΅Π½Π½ΡΠΌΒ Β ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌΒ» (n = 55,Β ΡΠΊΠΎΡΠΎΡΡΡΒ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡΒ 0,13Β Π΅Π΄. ΡΠΈΠ±ΡΠΎΠ·Π° / Π³ΠΎΠ΄).Β Β Β ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅Β Β ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Β Π³Π΅Π½ΠΎΠ²Β ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡΒ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ. ΠΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ², Π°Β ΡΠ°ΠΊΠΆΠ΅Β ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎΒ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Β ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π½Π° ΡΠΊΠΎΡΠΎΡΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠ‘ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π»ΠΎΠ³ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΈ.Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.Β Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ Ρ Π±ΡΡΡΡΡΠΌ ΡΠ΅ΠΌΠΏΠΎΠΌ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π° ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΡΒ Β Β Β (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ°Β Β ΠΠ°Π»ΡΠ΄Π° = 14,955; p = 0,00011),Β Β Β Β Β Β ΠΌΡΠΆΡΠΊΠΎΠΉΒ Β Β Β Β Β ΠΏΠΎΠ»Β Β Β Β Β Β (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° = 6,787; p = 0,00918), Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎΒ (-6)ΠΠ Π³Π΅Π½ΠΎΡΠΈΠΏΠ°Β Π³Π΅Π½Π°Β AGT (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° ΠΠ°Π»ΡΠ΄Π° = 6,512; p = 0,01072),Β 242Π’Π’-Π³Π΅Π½ΠΎΡΠΈΠΏΠ°Β Π³Π΅Π½Π°Β CYBAΒ (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ°Β ΠΠ°Π»ΡΠ΄Π° = 4,347;Β p = 0,03708)Β ΠΈΒ 235ΠΠ’Β Π³Π΅Π½ΠΎΡΠΈΠΏΠ°Β Β Π³Π΅Π½Π°Β Β AGT (ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ°Β ΠΠ°Π»ΡΠ΄Π° = 4,306; p = 0,03799). ΠΠΎΡΡΡΠΎΠ΅Π½Π° ΠΌΠΎΠ΄Π΅Π»Ρ, ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠ°Ρ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΒ Π±ΡΡΡΡΠΎΠ³ΠΎΒ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠ±ΡΠΎΠ·Π°Β Ρ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎΒ Π₯ΠΠ‘Β Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈΒ Π²ΡΡΠ΅ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½Π½ΡΡ
Β ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π΅Π΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅Β Π½Π° Π΄Π²ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠΌΠ΅ΡΠ°Ρ
.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠΈΡΠΊΠΎΠΌ Β«Π±ΡΡΡΡΠΎΠ³ΠΎΒ» ΡΠ°Π·Π²ΠΈΡΠΈΡΒ ΡΠΈΠ±ΡΠΎΠ·Π°Β ΠΏΠ΅ΡΠ΅Π½ΠΈΒ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΒ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π°Π½Π°Π»ΠΈΠ·Π° ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π°Β AGT (Π»ΠΎΠΊΡΡΡ M235T ΠΈ G-6A) ΠΈ Π³Π΅Π½Π°Β Π‘YBA (Π»ΠΎΠΊΡΡ C242T). ΠΠ΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈΒ Π² ΡΡΠΎΠΌ ΡΠ»ΡΡΠ°Π΅ ΡΠ²Π»ΡΡΡΡΡ Π³Π΅Π½ΠΎΡΠΈΠΏΡ 242Π’Π’ Π³Π΅Π½Π° CYBA, (-6)AA ΠΈ 235MT Π³Π΅Π½Π° AGT. ΠΠ»Ρ ΡΡΠΎΡΠ½Π΅Π½ΠΈΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°Β Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ (ΠΏΠΎΠ» ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΒ Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ) β ΠΌΡΠΆΡΠΊΠΎΠΉ ΠΏΠΎΠ» ΠΈ Π±ΠΎΠ»Π΅Π΅Β ΡΡΠ°ΡΡΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΡΒ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡΒ Π±ΡΡΡΡΠΎΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π₯ΠΠ‘